Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy

Figure 1 Baseline serum cytokine levels according to tumor characteristics. A, C, D, E, F and G: There were no significant differences in serum cytokine levels according to sex, BCLC stage, portal vein thrombosis, multiplicity and level of alpha-fetoprotein; B: When comparing stage II with stage IV, interleukin (IL)-8 levels showed a significant difference (^aP = 0.006) and IL-6 showed a borderline significance (P = 0.051); H: Treatment-non-naïve patients showed higher baseline serum IL-6 levels than treatment-naïve patients (^aP = 0.028).

Figure 2 Infield failure-free survival according to cut-off value of baseline serum interleukin-6. A: The cut-off value of interleukin (IL)-6 was obtained from a receiver operating characteristic (ROC) curve based on the Youden index (AUC, 0.748, P = 0.003, 95%CI: 1.011-1.028); B: Patients with baseline serum IL-6 level higher than 9.7 pg/mL showed worse infield FFS than those with baseline serum IL-6 level lower than 9.7 pg/mL (47.5% vs 100%, P = 0.005); C and D: In subgroup analysis, the significant difference of infield FFS was observed only in treatment-non-naïve patients (P = 0.022).